Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.
SPC3 is a synthetic multibranched peptide containing eight HIV-1 gp120 V3 loop GPGRAF motifs. SPC3 inhibits HIV-1 infection in human lymphocytes and macrophages, while the monomer counterpart of SPC3, i.e., the GPGRAF peptide, has no effect. Circular dichroism (CD) of these molecules in phosphate buffer, pH 7, and in a water solution containing 50% trifluoroethanol (TFE) showed significant differences. In TFE, the inactive monomer has a CD spectrum associated to type II beta-turn (class B spectrum), while SPC3 has a class C CD spectrum associated to type I beta-turn. To investigate the structure--function relationship, SPC3 analogs were built in solid-phase synthesis, and their activity and structures were compared to SPC3. Analogs having respectively two and four GPGRAF motifs show that polymerization is associated with these structural changes. Analogs with eight motifs but differing in their sequence show also that the sequence is important to stabilize a type I beta-turn structure. The activity tests of these analogs show a remarkable correlation between the antiviral activity and their ability to exhibit a class C CD spectrum associated to type I beta-turn. Taking in account CD results, a model was made using energy minimization and dynamics, which shows that, for SPC3, a model with motifs in a type I beta-turn structure is favored compared to one with a type II beta-turn. These data suggest that the SPC3 antiviral activity is related to the structure of the GPGRAF motif in the polymer, with special emphasis on the presence of a type I beta-turn structure.
Mabrouk
K
K
Laboratoire de Biochimie, CNRS URA 1455, IFR Jean Roche-Faculté de Médecine Nord, Marseille, France.
Van Rietschoten
J
J
Rochat
H
H
Loret
E P
EP
D000595:Amino Acid Sequence; D000998:Antiviral Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D002478:Cells, Cultured; D002942:Circular Dichroism; D015726:Giant Cells / Q000187:drug effects; D015699:HIV Envelope Protein gp120 / Q000737:chemistry* / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology; D008958:Models, Molecular; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D011487:Protein Conformation; D017433:Protein Structure, Secondary; D013329:Structure-Activity Relationship
D000998:Antiviral Agents; D015699:HIV Envelope Protein gp120; D010446:Peptide Fragments